Literature DB >> 7231282

Melioidosis in the Northern Territory of Australia.

J W Rode, D D Webling.   

Abstract

Melioidosis is being diagnosed with increasing frequency in the northern part of the Northern Territory, but the mortality rate remains high in the acute septicaemic form of the disease largely because of associated chronic debilitating illnesses. This paper reviews epidemiological and clinical features of human melioidosis in 37 cases seen between 1960 and 1979. Infection with Pseudomonas pseudomallei is most often contracted during the wet season by persons who have regular contact with soil or ground water, probably through pre-existing skin lesions or penetrating wounds and, occasionally, through the genitourinary tract. The clinical features of melioidosis are protean, and definitive diagnosis can only be made by bacterial culture. Certain strongly indicative features, however, may justify vigorous early treatment with antibiotics (tetracycline or doxycycline in some combination with chloramphenicol, kanamycin or trimethoprim/sulphamethoxazole) which can be life-saving in fulminant septicaemic melioidosis. These indicative features are a severely prostrating fever with signs of respiratory tract infection in a patient with a chronic debilitating condition (particularly chronic alcoholism, diabetes mellitus, malnutrition or leprosy), with regular soil contact, and with chronic or recurrent skin lesions or a recent history of a penetrating wound. In subacute or chronic forms of melioidosis, which usually localize in an organ system, the diagnosis is commonly an unexpected bacteriological finding and the prognosis is generally good.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231282     DOI: 10.5694/j.1326-5377.1981.tb135443.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  11 in total

1.  Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei.

Authors:  Peter Lowe; Catherine Engler; Robert Norton
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Effects of soil pH, temperature and water content on the growth of Burkholderia pseudomallei.

Authors:  Y S Chen; S C Chen; C M Kao; Y L Chen
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

3.  An ELISA-disc procedure for antibodies toPseudomonas pseudomallei: application for a serological study of melioidosis in an endemic area.

Authors:  N Embi; D Devarajoo; R Mohamed; G Ismail
Journal:  World J Microbiol Biotechnol       Date:  1993-01       Impact factor: 3.312

4.  In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei.

Authors:  L R Ashdown
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 5.  Melioidosis: the tip of the iceberg?

Authors:  D A Dance
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

6.  RAPD analysis of isolates of Burkholderia pseudomallei from patients with recurrent melioidosis.

Authors:  A Haase; A Melder; H Smith-Vaughan; D Kemp; B Currie
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

7.  Burkholderia pseudomallei musculoskeletal infections (melioidosis) in India.

Authors:  Vivek Pandey; Sripathi P Rao; Sugandhi Rao; Kiran Kv Acharya; Sarabjeet Singh Chhabra
Journal:  Indian J Orthop       Date:  2010-04       Impact factor: 1.251

8.  Musculoskeletal melioidosis: clinical and imaging features.

Authors:  M H Pui; A P Tan
Journal:  Skeletal Radiol       Date:  1995-10       Impact factor: 2.199

9.  Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Authors:  Ediane B Silva; Andrew Goodyear; Marjorie D Sutherland; Nicole L Podnecky; Mercedes Gonzalez-Juarrero; Herbert P Schweizer; Steven W Dow
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

10.  Siderophore production by Pseudomonas pseudomallei.

Authors:  H M Yang; W Chaowagul; P A Sokol
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.